HR and breast carcinoma: To further affirm this observation, we extended our investigation to a broader context by examining the expression patterns of LINC00960 across diverse breast cancer subtypes within the TCGA BRCA dataset, encompassing TNBC (n = 88), HER2+ (n = 33), HR+ (n = 351), and HR + HER2+ (n = 99) cases.